ITK and B-cell chronic lymphocytic leukemia: Ibrutinib treatment restored their function and cytotoxicity (88), which may be associated with the fact that ibrutinib promotes the phenotype of Vδ2Vγ9 T cells skewing toward Th1 cells in CLL patients by inhibiting ITK (87, 88).